Signet Therapeutics, a clinical-stage biotechnology company utilizing organoid and AI models to develop target cancer drugs, announced that its latest preclinical research findings on SIGX1094, the world's first targeted therapy for diffuse gastric cancer (DGC), will be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. This presentation will be the first public disclosure of SIGX1094’s core differentiation mechanism, highlighting its superior preclinical efficacy as the world’s first clinical-stage dual FAK/SRC inhibitor.
In addition to its potential as the world’s first targeted therapy for DGC, preclinical data also demonstrate SIGX1094’s potential as a monotherapy in other aggressive metastatic cancers, including ovarian cancer, triple-negative breast cancer, and pancreatic cancer. SIGX1094 has also demonstrated synergistic effect when combined with chemotherapy, as well as with targeted therapies for KRAS- and EGFR-mutant cancers.
Diffuse gastric cancer (DGC) is an aggressive malignancy with limited treatment options and no approved targeted therapies. Signet’s team’s previous research has identified the Focal Adhesion Kinase (FAK) as a novel and promising target for DGC. To enhance the efficacy of FAK inhibition in cancer therapy, Signet developed a potent small-molecule inhibitor, SIGX1094, which targets both FAK and the related kinase SRC. Whereas current FAK inhibitors in clinical trials only inhibit p-FAK. FAK and its key binding partner SRC form a complex that activates critical downstream pathways involved in cancer progression. Inhibiting only FAK or SRC individually often triggers compensatory mechanisms that reduce therapeutic efficacy. Signet Therapeutics has developed SIGX1094, the first dual FAK/SRC inhibitor, by leveraging organoid disease modeling for phenotypic screening and integrating AI-driven drug design. This novel approach significantly enhances the anti-tumor efficacy of the drug, offering a promising new treatment strategy for DGC.
Details regarding the Signet Therapeutics presentations at AACR 2025 are as follows:
Title: Discovery of SIGX1094R, a novel FAK inhibitor simultaneously blocking FAK and SRC signaling
Date/Time: Monday, April 28, 2025, from 2:00 p.m. - 5:00 p.m. CT
Location: Poster Section 20
Poster Board Number: 19
Published Abstract Number: 3018
About Signet Therapeutics
Signet Therapeutics is a clinical-stage biotech company pioneering the development of first-in-class targeted cancer therapies using organoids and AI. The company has successfully secured nearly $31 million in funding and has been recognized in Forbes Asia 100 to Watch list. The company’s lead pipeline, SIGX1094, has entered Phase I clinical trials as a potential first-in-class targeted therapy for diffuse gastric cancer, a highly aggressive cancer with no approved targeted treatments. SIGX1094 has achieved FDA Orphan Drug Designation and Fast Track Designation. In addition to advancing its own pipeline, Signet’s organoid platform is available for external collaborations, providing innovative preclinical drug discovery and development services to biotech and pharmaceutical partners.